• Investing Insights & Exclusive Offers → Get Our FREE “Market Brief”
    Sign-up for our free weekly newsletter. Get unparalleled investing insights and exclusive Summer Sale discounts on Hedgeye research.

    Disclaimer: By joining our email marketing list you agree to receive marketing emails from Hedgeye. You may unsubscribe at any time by clicking the unsubscribe link in one of the emails. Use of Hedgeye and any other products available through hedgeye.com are subject to our Terms Of Service and Privacy Policy

Takeaway: Replay - Breakdown with time stamped topics

REPLAY | State of Play | Congress' Ambitious Drug Price Agenda

Healthcare & Health Policy SubscribersCLICK HERE for video & audio replays.

(For unccoperative browers, cut and past: https://app.hedgeye.com/feed_items/76718)

On July 30, Macro Policy analyst, J.T. Taylor and I recapped the state of play for Congressional efforts to reform drug price policy in the US.

In this brief call, we went through:

Introduction:17 -2:47

Major Themes: 2:47 - 6:27

Drug Prices: 6.27 - 10:41

White House Position 10:41-12:24

CBO Scores: 12:24 - 13:15

Changes to Part D Benefit Design 13:16 - 16:15

Impact of Changes to Part D Benefit Design: 16:16-18:10

Part D Price Increase History: 18:12 - 19:07

Part B Drug Increases: 19:07-19:52

Lobbyist Positions: 19:53-22:35

What to Watch: 22:35-26:26

Comments from JT Taylor: 26:26-30:51

Q & A: 30:52-26:21

Emily Evans
Managing Director – Health Policy